Trial intelligence / Profile preview

Antineoplaston A10 and AS2-1 in Refractory/Recurrent High-Grade Non-Hodgkin's Lymphoma

NCT00003501Phase 2Terminated

Sponsor
Burzynski Research Institute
Start
Apr 1996
Primary completion
Jul 2003
Modality
Peptides, Small Molecules
Countries
1
01

Overview

A Phase 2 trial of antineoplaston A10, antineoplaston AS2-1 in non-Hodgkin lymphoma (NHL), sponsored by Burzynski Research Institute. Started Apr 1996; status: terminated.

02

Drugs

antineoplaston A10antineoplaston AS2-1
03

Conditions

non-Hodgkin lymphoma (NHL)

Beyond the preview

Go deeper on NCT00003501.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00003501.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call